Search PubMed⌕ Search

Biomedical subjects

A Ghezzi

Publications and source records attributed to A Ghezzi.

120 records · Page 7Linked to original sources
PubMedDate not supplied

A study of neuropsychological alterations in multiple sclerosis.

The Luria-Nebraska Neuropsychological Battery was administered to 22 patients with ascertained multiple sclerosis. The result is tht in these patients a brain damage exists in 54.5% of cases, but without preferential localization of the damage. Furthermore, the damage is not significantly correlated to four clinical parameters of the illness: age of the patient, age of the onset of the illness, duration of the illness and disability level.

Adult↗
PubMedDate not supplied

Electrophysiological tests and CSF examination in patients with optic neuritis.

Electrophysiological tests (visual and somatosensory evoked potentials, flicker fusion test) and electrophoretic examination of cerebrospinal fluid were performed in 17 patients who previously suffered from one or more attacks of optic neuritis. The association of the tests revealed the demyelinating inflammatory pathogenesis in eight cases. In the remaining nine cases the CSF oligoclonal pattern was absent. The evidence that a bilateral delayed VEP, suggesting a subclinical contralateral involvement of optic pathways, could be related to multiple sclerosis, is discussed. A case was finally ascertained as being affected by Leber's optic atrophy.

Adolescent↗
PubMedDate not supplied

[Multiple sclerosis: epidemiological research in the province of Varese].

Epidemiological research has been carried out on multiple sclerosis in the province of Varese. The index of prevalence of the disease at 31-12-1975 was 24.176%. The geomedical figures for the province are reported and a comparison made with similar research carried out in 1966. The clinical aspects of the disease are discussed in relation to a group of patients from other Italian provinces.

Adolescent↗
PubMedDate not supplied

[Effects of 2 single oral doses of mesoglycan on the coagulation-fibrinolysis system in man. A pharmacodynamic study].

In this study the profibrinolytic activity of two single oral doses of mesoglycan was evaluated. Furthermore, a mathematical model describing the patterns of the resulting phenomena was applied. Ten patients with impaired fibrinolytic system (euglobulin lysis time > 180 min) were enrolled in the study. In the morning following a 24 hour fast period, the patients were given orally a single dose (100 and 50 mg) of mesoglycan and placebo, with an interval of 48 hours between each treatment. The following parameters were evaluated at the time 0 and after 2, 4, 6, 8, 10 and 12 hours from each administration: tissue plasminogen activator (t-PA) and its inhibitor PAI-1, euglobulin lysis time, plasminogen and alfa-2-antiplasmin as indexes of the fibrinolytic system; aPTT, TT, fibrinogen as indexes of the hemostatic-coagulative system. Mesoglycan showed a dose-dependent profibrinolytic activity, that was also present after placebo but in a less entity. The mathematical study confirms the experimental observations and thus may allow to describe, with a high degree of approximation, the in vivo pharmacology of mesoglycan through the use of the mathematical function.

Administration, Oral↗
PubMedDate not supplied

[Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man].

We evaluated the mesoglycan effects on the coagulative-fibrinolytic system in 10 patients with euglobulin lysis time (ELT) over 180 minutes. A mathematical model was used to analyze such phenomena. 100 mg of mesoglycan was administered to 10 patients for 14 days. The following parameters were evaluated: tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), euglobulin lysis time (ELT), plasminogen, alpha 2 antiplasmin, prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), and fibrinogen. Those parameters were evaluated on the first and on the last day of the mesoglycan treatment at the following times: 0 (basal), 2, 4, 6, 8, 10 and 12 hours. Our results suggest that the mesoglycan is able to reduce a profibrinolytic activity without any influence on the coagulative-fibrinolytic system, at the baseline conditions and after chronic administration. The pharmacodynamic study and the statistical analysis using our mathematic model resulted to be statistically significant.

Adult↗